Stockreport

Celcuity Highlights Gedatolisib Breast Cancer Data, Near-Term Mutant Readout at Leerink Conference [Yahoo! Finance]

Celcuity Inc.  (CELC) 
Last celcuity inc. earnings: 3/12 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: celcuity.com/home/investors
PDF breast cancer — the triplet (gedatolisib + palbociclib + fulvestrant) showed median PFS of 9.3 vs 2 months with a hazard ratio of 0.24, supporting the company's thesis t [Read more]